PPAR-γ agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease

Daisuke Yoshihara, Hiroki Kurahashi, Miwa Morita, Masanori Kugita, Yoshiyuki Hiki, Harold M. Aukema, Tamio Yamaguchi, James P. Calvet, Darren P. Wallace, Shizuko Nagao

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

In autosomal recessive polycystic kidney disease (ARPKD), progressive enlargement of fluid-filled cysts is due to aberrant proliferation of tubule epithelial cells and transepithelial fluid secretion leading to extensive nephron loss and interstitial fibrosis. Congenital hepatic fibrosis associated with biliary cysts/dilatations is the most common extrarenal manifestation in ARPKD and can lead to massive liver enlargement. Peroxisome proliferator- activated receptor γ (PPAR-γ), a member of the ligand-dependent nuclear receptor superfamily, is expressed in a variety of tissues, including the kidneys and liver, and plays important roles in cell proliferation, fibrosis, and inflammation. In the current study, we determined that pioglitazone (PIO), a PPAR-γ agonist, decreases polycystic kidney and liver disease progression in the polycystic kidney rat, an orthologous model of human ARPKD. Daily treatment with 10 mg/kg PIO for 16 wk decreased kidney weight (% of body weight), renal cystic area, serum urea nitrogen, and the number of Ki67-, pERK1/2-, and pS6-positive cells in the kidney. There was also a decrease in liver weight (% of body weight), liver cystic area, fibrotic index, and the number of Ki67-, pERK1/2-, pERK5-, and TGF-β-positive cells in the liver. Taken together, these data suggest that PIO inhibits the progression of polycystic kidney and liver disease in a model of human ARPKD by inhibiting cell proliferation and fibrosis. These findings suggest that PPAR-γ agonists may have therapeutic value in the treatment of the renal and hepatic manifestations of ARPKD.

Original languageEnglish
Pages (from-to)F465-F474
JournalAmerican Journal of Physiology - Renal Physiology
Volume300
Issue number2
DOIs
Publication statusPublished - 01-02-2011

Fingerprint

Autosomal Recessive Polycystic Kidney
Peroxisome Proliferator-Activated Receptors
pioglitazone
Kidney Diseases
Liver Diseases
Polycystic Kidney Diseases
Liver
Kidney
Fibrosis
Body Weight
Cell Proliferation
Cyst Fluid
Fluids and Secretions
Weights and Measures
Nephrons
Cytoplasmic and Nuclear Receptors
Disease Progression
Urea
Cysts
Dilatation

All Science Journal Classification (ASJC) codes

  • Physiology
  • Urology

Cite this

Yoshihara, Daisuke ; Kurahashi, Hiroki ; Morita, Miwa ; Kugita, Masanori ; Hiki, Yoshiyuki ; Aukema, Harold M. ; Yamaguchi, Tamio ; Calvet, James P. ; Wallace, Darren P. ; Nagao, Shizuko. / PPAR-γ agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. In: American Journal of Physiology - Renal Physiology. 2011 ; Vol. 300, No. 2. pp. F465-F474.
@article{630e570f51cd4acbb1e8146bd2c6f980,
title = "PPAR-γ agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease",
abstract = "In autosomal recessive polycystic kidney disease (ARPKD), progressive enlargement of fluid-filled cysts is due to aberrant proliferation of tubule epithelial cells and transepithelial fluid secretion leading to extensive nephron loss and interstitial fibrosis. Congenital hepatic fibrosis associated with biliary cysts/dilatations is the most common extrarenal manifestation in ARPKD and can lead to massive liver enlargement. Peroxisome proliferator- activated receptor γ (PPAR-γ), a member of the ligand-dependent nuclear receptor superfamily, is expressed in a variety of tissues, including the kidneys and liver, and plays important roles in cell proliferation, fibrosis, and inflammation. In the current study, we determined that pioglitazone (PIO), a PPAR-γ agonist, decreases polycystic kidney and liver disease progression in the polycystic kidney rat, an orthologous model of human ARPKD. Daily treatment with 10 mg/kg PIO for 16 wk decreased kidney weight ({\%} of body weight), renal cystic area, serum urea nitrogen, and the number of Ki67-, pERK1/2-, and pS6-positive cells in the kidney. There was also a decrease in liver weight ({\%} of body weight), liver cystic area, fibrotic index, and the number of Ki67-, pERK1/2-, pERK5-, and TGF-β-positive cells in the liver. Taken together, these data suggest that PIO inhibits the progression of polycystic kidney and liver disease in a model of human ARPKD by inhibiting cell proliferation and fibrosis. These findings suggest that PPAR-γ agonists may have therapeutic value in the treatment of the renal and hepatic manifestations of ARPKD.",
author = "Daisuke Yoshihara and Hiroki Kurahashi and Miwa Morita and Masanori Kugita and Yoshiyuki Hiki and Aukema, {Harold M.} and Tamio Yamaguchi and Calvet, {James P.} and Wallace, {Darren P.} and Shizuko Nagao",
year = "2011",
month = "2",
day = "1",
doi = "10.1152/ajprenal.00460.2010",
language = "English",
volume = "300",
pages = "F465--F474",
journal = "American Journal of Physiology - Renal Physiology",
issn = "1931-857X",
publisher = "American Physiological Society",
number = "2",

}

PPAR-γ agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease. / Yoshihara, Daisuke; Kurahashi, Hiroki; Morita, Miwa; Kugita, Masanori; Hiki, Yoshiyuki; Aukema, Harold M.; Yamaguchi, Tamio; Calvet, James P.; Wallace, Darren P.; Nagao, Shizuko.

In: American Journal of Physiology - Renal Physiology, Vol. 300, No. 2, 01.02.2011, p. F465-F474.

Research output: Contribution to journalArticle

TY - JOUR

T1 - PPAR-γ agonist ameliorates kidney and liver disease in an orthologous rat model of human autosomal recessive polycystic kidney disease

AU - Yoshihara, Daisuke

AU - Kurahashi, Hiroki

AU - Morita, Miwa

AU - Kugita, Masanori

AU - Hiki, Yoshiyuki

AU - Aukema, Harold M.

AU - Yamaguchi, Tamio

AU - Calvet, James P.

AU - Wallace, Darren P.

AU - Nagao, Shizuko

PY - 2011/2/1

Y1 - 2011/2/1

N2 - In autosomal recessive polycystic kidney disease (ARPKD), progressive enlargement of fluid-filled cysts is due to aberrant proliferation of tubule epithelial cells and transepithelial fluid secretion leading to extensive nephron loss and interstitial fibrosis. Congenital hepatic fibrosis associated with biliary cysts/dilatations is the most common extrarenal manifestation in ARPKD and can lead to massive liver enlargement. Peroxisome proliferator- activated receptor γ (PPAR-γ), a member of the ligand-dependent nuclear receptor superfamily, is expressed in a variety of tissues, including the kidneys and liver, and plays important roles in cell proliferation, fibrosis, and inflammation. In the current study, we determined that pioglitazone (PIO), a PPAR-γ agonist, decreases polycystic kidney and liver disease progression in the polycystic kidney rat, an orthologous model of human ARPKD. Daily treatment with 10 mg/kg PIO for 16 wk decreased kidney weight (% of body weight), renal cystic area, serum urea nitrogen, and the number of Ki67-, pERK1/2-, and pS6-positive cells in the kidney. There was also a decrease in liver weight (% of body weight), liver cystic area, fibrotic index, and the number of Ki67-, pERK1/2-, pERK5-, and TGF-β-positive cells in the liver. Taken together, these data suggest that PIO inhibits the progression of polycystic kidney and liver disease in a model of human ARPKD by inhibiting cell proliferation and fibrosis. These findings suggest that PPAR-γ agonists may have therapeutic value in the treatment of the renal and hepatic manifestations of ARPKD.

AB - In autosomal recessive polycystic kidney disease (ARPKD), progressive enlargement of fluid-filled cysts is due to aberrant proliferation of tubule epithelial cells and transepithelial fluid secretion leading to extensive nephron loss and interstitial fibrosis. Congenital hepatic fibrosis associated with biliary cysts/dilatations is the most common extrarenal manifestation in ARPKD and can lead to massive liver enlargement. Peroxisome proliferator- activated receptor γ (PPAR-γ), a member of the ligand-dependent nuclear receptor superfamily, is expressed in a variety of tissues, including the kidneys and liver, and plays important roles in cell proliferation, fibrosis, and inflammation. In the current study, we determined that pioglitazone (PIO), a PPAR-γ agonist, decreases polycystic kidney and liver disease progression in the polycystic kidney rat, an orthologous model of human ARPKD. Daily treatment with 10 mg/kg PIO for 16 wk decreased kidney weight (% of body weight), renal cystic area, serum urea nitrogen, and the number of Ki67-, pERK1/2-, and pS6-positive cells in the kidney. There was also a decrease in liver weight (% of body weight), liver cystic area, fibrotic index, and the number of Ki67-, pERK1/2-, pERK5-, and TGF-β-positive cells in the liver. Taken together, these data suggest that PIO inhibits the progression of polycystic kidney and liver disease in a model of human ARPKD by inhibiting cell proliferation and fibrosis. These findings suggest that PPAR-γ agonists may have therapeutic value in the treatment of the renal and hepatic manifestations of ARPKD.

UR - http://www.scopus.com/inward/record.url?scp=79551566710&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79551566710&partnerID=8YFLogxK

U2 - 10.1152/ajprenal.00460.2010

DO - 10.1152/ajprenal.00460.2010

M3 - Article

C2 - 21147840

AN - SCOPUS:79551566710

VL - 300

SP - F465-F474

JO - American Journal of Physiology - Renal Physiology

JF - American Journal of Physiology - Renal Physiology

SN - 1931-857X

IS - 2

ER -